Mad Hedge Biotech & Healthcare Letter
January 5, 2021
Fiat Lux
FEATURED TRADE:
(ANNOUNCING THE MAD HEDGE BIOTECH AND HEALTH CARE TRADE ALERT SERVICE)
(WHY ASTRAZENECA IS NOT JUST A COVID PLAY)
(AZN), (PFE), (MRNA), (JNJ), (ALXN)
Mad Hedge Biotech & Healthcare Letter
January 5, 2021
Fiat Lux
FEATURED TRADE:
(ANNOUNCING THE MAD HEDGE BIOTECH AND HEALTH CARE TRADE ALERT SERVICE)
(WHY ASTRAZENECA IS NOT JUST A COVID PLAY)
(AZN), (PFE), (MRNA), (JNJ), (ALXN)
I am pleased to announce the launch of the Mad Hedge Biotech & Healthcare Trade Alert Service.
The goal is to alert traders and investors when entry sweet spots occur for Biotech & Healthcare stocks with the strongest long-term fundamentals.
Don’t expect any immediate trade alerts today, tomorrow, this week, or even this month. Actual market sweet spots are rare and only take place after prolonged bottoming processes. However, they DO make it easier for investors to move into the best companies at the right time and achieve immediate profits.
Each alert will include recommendations for the stock, options, and ETF so you can tailor the position to your own level of experience and risk tolerance.
In order to receive Biotech text alerts, we need your cell phone number to get text messages to you immediately. To register, please click here.
I look forward to working with you with this service.
John Thomas
CEO & Publisher
The Mad Hedge Biotech & Healthcare Letter
The latest update on AstraZeneca’s (AZN) COVID-19 vaccine candidate has received a lot of attention from investors.
The company and its research partner Oxford University recently landed a deal to deliver 2 million doses of their COVID-19 vaccine weekly to the UK starting mid-January.
This is on top of the massive deal AstraZeneca sealed with India for emergency use approval as well.
While these are exciting updates, the reality is that AstraZeneca aims to market its COVID-19 vaccine candidate at cost.
As the race to supply COVID-19 vaccine to the world continues, it’s undeniable that a huge chunk of the roughly $40 billion COVID-19 revenue would go to the current frontrunners Pfizer (PFE) and Moderna (MRNA).
This is particularly true for Moderna’s case as the biotechnology company employed a revolutionary technology to create its COVID-19 vaccine candidate.
The success of its vaccine so far is indicative of future treatments and even vaccines based on the mRNA technology. This offers incredible promise not only for the current pandemic but for a myriad of rare diseases.
In comparison, AstraZeneca and even Johnson & Johnson (JNJ) opted for more traditional approaches for their COVID-19 vaccine candidates.
While these are also promising, it’s likely that these companies do not anticipate their COVID-19 programs to be the profit centers for 2021.
In fact, there are a lot of good reasons to buy AstraZeneca shares right now – and its COVID-19 vaccine candidate didn’t make the top of the list.
One of the main reasons AstraZeneca deserves a spot in your portfolio is the fact that it already has an established and successful pipeline.
While its COVID-19 program definitely boosted its popularity, this effort was not altogether necessary in terms of the company’s overall growth.
Despite the pandemic that brought down businesses in 2020, including commercial launches of new drugs, sales of AstraZeneca’s new products rose 9% year over year.
In fact, throughout the past 12 months, the company managed to generate approximately $1.9 billion in free cash flow.
In the first nine months of 2020, the company reported core earnings growth of 13% year over year, with a 2.8% dividend.
To close the year with a bang, AstraZeneca announced its $39 billion acquisition of one of our closely-watched biotechnology companies: Alexion Pharmaceuticals (ALXN).
Although this initially didn’t bode well with its investors, AstraZeneca is set to gain the blockbuster franchise composed of the Soliris-Ultomiris duo.
At its current growth rate, Alexion’s prized Soliris franchise is estimated to generate at least $6 billion in sales in 2021.
Meanwhile, Soliris’ longer-lasting version, Ultomiris, which was launched in 2018, is projected to rake in almost twice in profits this year.
Both Soliris and Ultomiris require regular treatment, with the former administered every other week while the latter is an infusion needed every other month.
Although there are less expensive biosimilar options already making the in the market today, particularly for Soliris, the move of Alexion to develop Ultomiris as a longer-lasting and more convenient version all but obliterates any future competition.
Simply put, AstraZeneca will have a monopoly of this market once the acquisition is complete by mid-2021.
Speaking of convenient options for prolonged treatments, AstraZeneca recently gained expanded approval for its easy-to-swallow tablet called Tagrisso. This drug is developed for lung cancer patients with tumors caused by specific gene mutations.
The latest approval allows Tagrisso to be prescribed to newly diagnosed patients who just had their tumors removed surgically.
This presents a lucrative market for AstraZeneca considering that these patients undergo therapy for long periods.
More importantly, AstraZeneca doesn’t really need to market Tagrisso’s value to oncologists.
Clinical results show that the tablet can lower the risk of the disease’s recurrence or even death by as much as 80% among their patients.
Putting these results in the context of AstraZeneca’s records, Tagrisso’s sales for the third quarter of 2020 alone grew by 30% year over year to reach $4.6 billion.
With the recent FDA approval, this number is set to increase to transform Tagrisso into a certified blockbuster drug.
Other than Tagrisso, AstraZeneca has a number of oncology blockbusters in its portfolio and pipeline.
In the first nine months of 2020, the sales of the company’s therapies unit rose by 23% year over year to a record $8.2 billion. Admittedly, Tagrisso contributed a substantial amount.
However, it’s not the sole growth driver in AstraZeneca’s oncology lineup.
Another moneymaker is Lynparza, which showed a 42% jump year over year in its third quarter sales in 2020 to reach $1.9 billion.
This drug, which was initially approved as an ovarian cancer treatment, is now prescribed to treat prostate, pancreatic, and breast cancer. Therefore, the expanded approvals are expected to offer more lift this year.
Another promising addition to AstraZeneca’s oncology pipeline is Enhertu, which the company gained from its $1.35 billion collaboration project with Daiichi Sankyo.
Since the two companies started working together last year, Enhertu has received approval for breast cancer patients who relapse or do not respond to standard care.
Aside from this, Enhertu is also under review as a treatment for stomach cancer.
Although the companies are still awaiting approval, the treatment is reported to have a great chance at approval because of its impressive ability to lower the risk of cancer patients’ death by 41% compared to chemotherapy.
AstraZeneca’s decision to boost its oncology segment by adding the likes of Alexion Pharmaceuticals and collaborating with Daiichi Sankyo guarantees that the company remains in a position to be able to deliver gains no matter what happens to the broader economy.
The continuous success for all the products in AstraZeneca’s pipeline could lead to market-crushing gains.
However, investors who own the stock don’t necessarily need to rely on luck to know that they are set to get a healthy return.
That assurance makes AstraZeneca a great stock to buy today and hold for a long time.
Global Market Comments
January 5, 2021
Fiat Lux
Featured Trade:
(NOTICE TO MILITARY SUBSCRIBERS),
(CHINA’S COMING DEMOGRAPHIC NIGHTMARE)
When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more
Mad Hedge Technology Letter
January 4, 2021
Fiat Lux
Featured Trade:
(SPLINTERNET GOES FROM BAD TO WORSE IN 2021)
(AMZN), (APPL), (TIKTOK), (TWTR), (MSFT), (GOOGL), (FB)
The balkanization of the internet is exploding in the short-term, knocking off the aggregated value of U.S. Fortune 500 companies in one fell swoop.
In technology terms, this is frequently referred to as “splinternet.”
A quick explanation for the novices can be summed up by saying the splinternet is the fragmenting of the Internet, causing it to divide due to powerful forces such as technology, commerce, politics, nationalism, religion, and interests.
What investors are seeing now is a hard fork of the global tech game into a multi-pronged world of conflicting tech assets sparring for their own digital territory.
The epicenter of balkanization is the division between China and the U.S. tech economy with India as the wild card.
This is fast becoming a winner-take-all affair.
Silicon Valley is winning in India due to border conflicts along the Himalayan Corridor.
India took count of 20 dead Indian soldiers felled by the Chinese Army stoking a wave of national outcry against regional rival China.
The backlash was swift with the Indian government banning 59 premium apps developed by China citing “national security and defense.”
The ban included the short-form video platform TikTok, which counts India as its biggest overseas market.
TikTok was projected to easily breeze past 500 million Indian users by the end of 2021 and was clearly hardest hit out of all the apps.
India is the second biggest base of global internet users with nearly half of its 1.3 billion population online.
The government rolled out the typical national security playbook saying that the stockpiling of local Indian data in Chinese servers undermines national security.
China’s inroads in the Indian tech market are set to wane with recent rulings already impacting roughly one in three smartphone users in India. TikTok, Club Factory, and UC Browser among other apps in aggregate tally more than 500 million monthly active users in May 2020.
Highlighting the magnitude of this purge - 27 of these 59 apps were among the top 1,000 Android apps in India.
China dove headfirst into the Indian market with their smartphones, apps, and an array of hardware equipment. Now, that is all on hold and looks like a terrible mistake.
Chinese smartphone makers command more than 80% of the smartphone market in India, which is the world’s second largest.
One of the reasons Apple (AAPL) could never make any headway in China is because they were constantly undercut by predatory Chinese phone makers with stolen technology.
It’s also not smooth saying for domestic Chinese tech as Chinese Chairman Xi reign in the private sector with Alibaba’s founder Jack Ma’s whereabouts unknown as we start the new year.
This is happening on the heels of the Chinese Communist Party thwarting the Alipay IPO in Shenzhen which was posed to become the biggest IPO ever.
TikTok is also being eyed-up for bans in Europe and the United States recently as it constantly curries to Beijing’s every whim by banning content unfavorable to the Chinese communist party and rerouting data back to servers in China.
Chinese tech is clearly the main loser for their government’s “distract its own people at all costs” campaign to shield themselves from the epic contagion of the lingering pandemic.
What does this mean for American tech?
For one, India is strengthening ties with the U.S., being the biggest democracy in Asia, and will be a massive foreign policy loss and loss of face for the Chinese communist regime.
The resulting losses for Chinese tech will usher in a new generation of local Indian tech with Silicon Valley mopping up the leftovers.
Even though the U.S. avoided the carnage from this round of balkanization, the situation in Europe is tenuous, to say the least.
Fault lines will compound the problem of a multinational tech revenue machine and the relationship with France is on the verge of becoming fractious.
The relationship is worsening with the Europeans by a trade deal consummated between the EU and China along with Western European powers such as France, Germany, and Britain looking to add to their tax coffers by taxing big tech companies like Facebook (FB), Twitter (TWTR), Google (GOOGL) in 2021.
This would be a massive blow to not only revenue streams but also global prestige for American tech.
Not only do Silicon Valley leaders see a murky future outside its borders, but digital territories are also getting carved out as we speak domestically.
Amazon (AMZN)-owned Twitch and Twitter have clamped down on U.S. President Donald Trump’s account.
This could quickly spiral into a left-versus-right war in which there are competing apps for different political beliefs and for every subgenre of apps.
This would effectively mean a balkanization of tech assets within U.S. borders and division in 2021 is set to extend itself.
Silicon Valley wants products sold to the largest addressable market possible and that simply won’t happen in 2021.
The balkanization of the internet is now turning into an equally high risk as the antitrust and regulatory issues.
The issues keep piling up, but nothing has been able to topple big tech yet as they lead the broader market out of the pandemic.
Silicon Valley is still subsidized by ultra-low interest rates and quantitative easing by the Fed. If this changes, look for tech to roll over.
Let’s hope that never happens.
“Over the next 10 years, we’ll reach a point where nearly everything has become digitized.” – Said Current CEO of Microsoft Satya Nadella
Global Market Comments
January 4, 2021
Fiat Lux
Featured Trade:
(REPORT FROM THE FROZEN WASTELANDS OF THE WEST)
I am writing this from a High Sierra peak at 12,000 feet in the dead of winter.
It is 15 degrees and the wind is gusting to 70 miles an hour, turning my backpack into a sail and practically blowing me off the mountain. Over the side, the next stop is 1,000 feet below. I am thirsty, but the water in my canteen is frozen solid.
I had planned to follow my tracks in the snow back down to my car, but the wind has totally obliterated them. So, I am using an old-fashioned army compass to navigate back in total whiteout conditions. Good thing I got the letter out early today!
Actually, I am not writing this, I am thinking it. If I took my hands out of my heavy mittens, my fingers would freeze in seconds. Remember, no fingers, no Trade Alerts!
A couple of times a year, I feel the need to abandon civilization and contemplate the meaning of life, while accomplishing a great physical challenge. For me, this is a mandatory religious experience.
This time, I attempted to emulate one of the great physical feats in history. In October 1847, the Donner Party’s wagon train was hopelessly snowed in at a Sierra pass. Starvation loomed. When word reached Sacramento, four rescue parties were sent out, only to be repulsed by driving blizzards.
Finally, a giant of heroic strength, the famous Snowshoe Thompson, who stood at 6’6” broke through. He emptied his massive wood frame backpack of food and then stuffed it with the two smallest children he could find. He snowshoed back to safety 120 miles over three days, nonstop. The kids grew up to become the founding fathers of modern-day Marin County, California.
I thought, “Gee, I wonder if I could do that?”
So I sought to replicate the feat, subject to a few modern compromises. Today, Interstate 80 sits astride Thompson’s original route. Instead, I'm determined to snowshoe 120 miles of the Tahoe Rim Trail around Lake Tahoe, with an average elevation of 9,000 feet. I figured that the 60-pound pack I usually carry was worth the weight of two kids.
My one concession to my advanced age was that instead of going nonstop or camping out at night, I would break the epic trek into ten days at 12 miles each. That allowed me to retire to my Tahoe lakefront estate nightly to thaw out my toes, treat injuries, and get some shuteye. Howling winds keep you awake at night.
I fasted while accomplishing this, eating only 600 calories a day of raw fruit and nuts. I’m down about ten pounds since I began.
Hint to readers: almonds have unique, hunger-fighting chemical properties. Eat a handful before you go to sleep, and hunger pangs won’t wake you in the middle of the night. I plan on doing some industrial-strength eating this Christmas, things like Tom and Jerry’s and Sees peanut brittle, so I need to get ahead of the curve. (Note to self: 223 calories in a cup of eggnog).
My friends call this a death march, make excuses why they can’t come, and worry about my sanity. I think of it as a cleansing and a general stocktaking, and I feel great! I always go alone. How many other 68-year olds do you know who are in the condition to do this sort of thing?
Sure, I might break my ankle someday, die of exposure, and have my bones scattered by wild animals. Who cares? It would be a good death. It’s worth it.
The scenery up here is so spectacular that I almost didn’t feel the pain. Almost. On more than one occasion, while gazing at the endless shades of blue the pristine waters of Lake Tahoe offered, I tripped on my snowshoes.
Once, I landed on some tree roots, which cut right through to the bone in my left forearm. I managed to stop the bleeding by tying off a tourniquet with my teeth. When I got home, I then soaked the wound in Jack Daniels to ward off infection. It works every time! (see pics below). In a pinch, Stolichnaya Vodka works just as well. It’s an old combat first aid trick.
While hiking along the East Ridge, succeeding mountain ranges in northern Nevada explored every kind of purple. I managed to summit each major peak around the body of water the Washoe Indians called “da-ow-a-ga”, or edge of the lake, which they considered the origin of the universe. Those included Squaw Peak (8,885), Mt Tallac (9,735 feet), Monument Peak (10,067), and Mount Rose (10,776 feet). When the trail got too steep, my trusty ice ax and crampons saw me through.
I was constantly reminded that I was in the “Old West” by the many artifacts I encountered. Prominent granite boulders displayed prehistoric Indian petroglyphs. I found a few abandoned log cabins, complete with potbelly stoves and canned food from the 1950s.
Rusted out cast iron mining equipment was strewn about everywhere, covered with snow. Along the old Pony Express Trail, one finds old horseshoes and the occasional ancient bottle turned purple by the sun.
Lake Tahoe supplied all of the water and bracing wood for the Comstock silver mining boom of the 1870s. A hundred years ago, not a single tree was left standing, except for the southwest section of the lake owned by mining baron “Lucky Baldwin” who won it in a card game and made it his private retreat.
It was all covered in meticulous and colorful detail for the Virginia City newspaper, The Territorial Enterprise, by a budding young newspaperman who went by the name of Mark Twain.
My ambitious goals often saw me hiking well into darkness. After the batteries died on my three backup headlamps, that flashlight app on the iPhone proved a real lifesaver. It’s good for a full hour and illuminates the eyes of onlooking wildlife a bright yellow up to 200 yards.
One night, I got back to the car and found that my keys had frozen. So I sat on them. In 15 minutes, the car flashed its lights and the doors magically opened. There was barely enough charge to get the engine started, a trick I accomplished by holding the key right up to the ignition button. Toyota designs them to do this. It’s no fun getting stranded at 10,000 feet at 10 degrees in the middle of nowhere. No Auto Club here!
I often looked behind to make sure a mountain lion was not stalking me. Don’t worry. Only 20 people have been killed by mountain lions in California over the last 100 years. More are killed by their pet dogs every year in the Golden State, mostly by pit bulls. Besides, I am good at staring down mountain lions and black bears. It is just a matter of attitude.
The old souvenir stand for the Ponderosa Ranch of the TV series Bonanza fame is now the Tunnel Creek Station Café and bike rental. Good luck to Patty and Max! The nearby Flume Trail offers some of the best cross-country skiing in the world.
Of course, I am not just thinking Great Thoughts during these hikes. An endless series of economic and market data points are constantly churning around in the back of my mind, and I occasionally reach a “Eureka” moment. I keep a pen and notebook in my pack so I don’t forget these earth-shaking revelations.
It was during a similar expedition up the face of the Matterhorn in the Swiss Alps (14,692 feet) last summer when I realized that the S&P was beginning a long run-up that would take it to 1,800 by yearend. I’ll never forget the expression on my guide’s face when I stopped midpoint through an abseil and started feverishly writing notes. That little maneuver cost me a bottle of schnapps. The readers and Trade Alert followers prospered mightily.
What is this year’s “Eureka” conclusion? The stock market could keep going up but with more volatility. This year was a cakewalk, as my 60% return testifies. After that, stocks will be unable to ignore an impending “taper”, or the complete end of quantitative easing. The bond market has told us as much already.
I have been doing this sort of thing since I was 22 and in somewhat better shape. Then, I was one of the few foreigners attending karate school in Japan, learning the iron discipline and focus of samurai warriors, known as “bushido”. The actor Steven Segal studied at a competing school down the street.
Every February, we underwent “kangeiko”, or “winter training." This involved the entire class running the five miles around Tokyo’s Imperial Palace in a pack, suffering freezing temperatures, barefoot, every day for a week. When we returned to the dojo, we were hosed down with ice-cold water, our feet senseless, bloody stumps. Then we would train for three more hours.
The idea was that the extreme pain and exhaustion would deliver insights into ourselves and the world at large. It worked. At least one current reader endured the experience with me and is still alive. Remember that, David? By the way, thanks for knocking out my front teeth.
On the way home, I stopped in Sacramento for a well-deserved double cheeseburger, fries, and chocolate shake at In and Out Burger. You can’t take this diet and health thing too seriously. Snowshoe Thompson would have envied me.
Well, next month, it is back to normal. I’ll be glued in front of my screens scouring the planet for the next great trading opportunity, although, I’m not sure I’ll find many. Buying market tops is against my nature. What are you supposed to do when all of your forecasts and predictions come true? I have a feeling that the answer is not to make more forecasts and predictions.
Perhaps, the right answer is to take another hike. Anyone care to join me?
Legal Disclaimer
There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.